- Home
- CWK vs ACLX Comparison
CWK vs ACLX Comparison
Compare CWK & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWK | ACLX |
|---|---|---|
| Founded | 1784 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.2B |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CWK | ACLX |
|---|---|---|
| Price | $16.31 | $64.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $17.56 | ★ $115.71 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 02-19-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.30 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $10,003,900,000.00 | $35,898,000.00 |
| Revenue This Year | $8.47 | N/A |
| Revenue Next Year | $2.02 | $293.08 |
| P/E Ratio | $17.09 | ★ N/A |
| Revenue Growth | ★ 6.77 | N/A |
| 52 Week Low | $7.64 | $47.86 |
| 52 Week High | $17.33 | $94.07 |
Technical Indicators
Market Signals| Indicator | CWK | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.45 | 36.97 |
| Support Level | $15.06 | $63.48 |
| Resistance Level | $16.65 | $66.79 |
| Average True Range (ATR) | 0.39 | 2.39 |
| MACD | 0.07 | 0.31 |
| Stochastic Oscillator | 73.35 | 19.09 |
Price Performance
Historical ComparisonAbout CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such as valuation, project management, and facilities management.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.